IP Library › Granted Patent US 11,931,163
Granted Patent B2
US 11,931,163 · App. 16/487,768 · Granted Mar 19, 2024

Method and apparatus to determine the malignant potential of pancreatic cysts using light scattering spectroscopy

Inventor: Lev T. Perelman (Brookline, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc.
A61B5/425A61B5/0075A61B5/0084A61B8/0841A61B10/0045A61B2010/0061A61B2562/0242
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,931,163
App. No.
16/487,768
Granted
Mar 19, 2024
Kind
B2
Abstract

Described herein are embodiments of an approach to diagnosing pancreatic cystic lesions using light scattering spectroscopy. In some embodiments, the approach includes an apparatus including a spatial gating probe to isolate light reflected by the epithelial tissue of the internal cyst surface using spatial gating. In some further embodiments, the apparatus includes a scanning fiber probe that is capable of rotational and linear motion in order to scan the entire internal surface of the cyst. Use of such an approach may be advantageous to improve the accuracy of diagnosing pancreatic cystic lesions as cancerous, precancerous, or benign.

Claims (61)

1. A spatial gating probe for performing light scattering spectroscopy on tissue, the spatial gating probe comprising:

a housing;

a plurality of fiber-optic cables disposed within the housing, wherein:

the plurality of fiber-optic cables comprises at least one source fiber and at least one detector fiber;

the at least one source fiber is configured to emit light onto the tissue;

the at least one detector fiber is configured to receive light reflected from the tissue;

the plurality of fiber-optic cables being constructed and arranged in a hexagonal shape such that the at least one source fiber is disposed at an outer edge of the hexagonal shape;

the at least one detector fiber comprises at least one first detector fiber and at least one second detector fiber;

the at least one first detector fiber is disposed at a distance d 1 from the at least one source fiber;

the at least one second detector fiber is disposed at a distance d 2 from the at least one source fiber; and

d 2 is greater than d 1 ; and

first and second spectrometers,

wherein the at least one first detector fiber is configured to obtain a first spectrum, and the at least one second detector fiber is configured to obtain a second spectrum,

wherein the first and second spectrometers are configured to analyze, respectively, the first spectrum and the second spectrum to subtract the second spectrum obtained by the at least one second detector fiber from the first spectrum obtained by the at least one first detector fiber,

wherein the first spectrum and second spectrum are unpolarized signals.

2. The spatial gating probe of claim 1 , wherein:

the spatial gating probe is configured to be inserted inside a pancreatic cyst;

the at least one source fiber is configured to emit light onto an inside surface of the pancreatic cyst; and

the at least one detector fiber is configured to receive light reflected from the inside surface of the pancreatic cyst.

3. The spatial gating probe of claim 1 , wherein:

the at least one first detector fiber is configured to receive light reflected from a surface of a pancreatic cyst; and

the at least one second detector fiber is configured to receive light reflected from a portion of the pancreatic cyst deeper than the surface of the pancreatic cyst.

4. The spatial gating probe of claim 1 , wherein d 2 is equal to 240 μm and d 1 is equal to 120 μm.

5. The spatial gating probe of claim 1 , wherein the first and second spectrometers are configured to analyze respectively the first spectrum and second spectrum to isolate light reflected from an epithelium layer of a pancreatic cyst in order to determine a malignant potential of the pancreatic cyst.

6. The spatial gating probe of claim 1 , wherein the first spectrum corresponds to light reflected from a surface of a pancreatic cyst, and the second spectrum corresponds to light reflected from a portion of the pancreatic cyst deeper than the surface.

7. An apparatus for determining a malignant potential of a pancreatic cyst, the apparatus comprising:

a fixed-length tube;

an endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) needle disposed at an end of the fixed-length tube; and

a spatial gating probe disposed within the EUS-FNA needle, the spatial gating probe comprising:

a housing; and

a plurality of fiber-optic cables disposed within the housing, wherein:

the plurality of fiber-optic cables comprises at least one source fiber and at least one detector fiber;

the at least one source fiber is configured to emit light onto the pancreatic cyst;

the at least one detector fiber is configured to receive light reflected from the pancreatic cyst;

the plurality of fiber-optic cables being constructed and arranged in a hexagonal shape such that the at least one source fiber is disposed at an outer edge of the hexagonal shape housing;

the at least one detector fiber comprises at least one first detector fiber and at least one second detector fiber;

the at least one first detector fiber is disposed at a distance d 1 from the at least one source fiber;

the at least one second detector fiber is disposed at a distance d 2 from the at least one source fiber; and

d 2 is greater than d 1

first and second spectrometers,

wherein the at least one first detector fiber is configured to obtain a first spectrum, and the at least one second detector fiber is configured to obtain a second spectrum,

wherein the first and second spectrometers are configured to analyze, respectively, the first spectrum and the second spectrum to subtract the second spectrum obtained by the at least one second detector fiber from the first spectrum obtained by the at least one first detector fiber,

wherein the first spectrum and second spectrum are unpolarized signals.

8. The apparatus of claim 7 , wherein:

the fixed-length tube is configured to be inserted orally into a patient;

the EUS-FNA needle is configured to be inserted inside the pancreatic cyst;

the at least one source fiber is configured to emit light onto an inside surface of the pancreatic cyst; and

the at least one detector fiber is configured to receive light reflected from the inside surface of the pancreatic cyst.

9. The apparatus of claim 7 , wherein:

the at least one first detector fiber is configured to receive light reflected from a surface of the pancreatic cyst; and

the at least one second detector fiber is configured to receive light reflected from a portion of the pancreatic cyst deeper than the surface of the pancreatic cyst.

10. The apparatus of claim 7 , wherein d 2 is equal to 240 μm and d 1 is equal to 120 μm.

11. The apparatus of claim 7 , wherein:

the at least one first detector fiber is connected to the at least one first spectrometer; and

the at least one second detector fiber is connected to the at least one second spectrometer.

12. The apparatus of claim 11 , wherein the at least one first and second spectrometers are configured to analyze the first and second spectrum to isolate light reflected from an epithelium layer of the pancreatic cyst in order to determine the malignant potential of the pancreatic cyst.

13. The apparatus of claim 11 , wherein the first spectrum corresponds to light reflected from the surface of the pancreatic cyst, and the second spectrum corresponds to light reflected from a portion of the pancreatic cyst deeper than the surface.

14. The spatial gating probe of claim 1 , wherein the housing is configured to contact the tissue.

15. The apparatus of claim 7 , wherein the housing is configured to contact the pancreatic cyst.

16. The apparatus of claim 7 , wherein the EUS-FNA needle is either a 22 gauge or a 19 gauge.

17. The apparatus of claim 7 , wherein an internal diameter of the EUS-FNA needle is less than or equal to 0.91 mm.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2019
From: PERELMAN, LEV T.
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 050200/0193 →
Continuity (3)
Provisional Application 62469982 · Mar 10, 2017
Provisional Application 62462510 · Feb 23, 2017
Related Publication 20200297266A1 · Sep 24, 2020